- Preliminary findings demonstrate improved clinical status in critically ill COVID-19 patients with acute respiratory distress syndrome (ARDS) receiving convalescent plasma containing neutralizing antibodies.
- Small clinical trials are underway in the United States and China.
- Related editorial details logistical considerations should the approach prove efficacious.
Why this matters
- Previous studies suggest potential utility of convalescent plasma in treating infections.
- Same-day collection, transfusion may help preserve natural activity of plasma.
- 5 patients, ages 36-73 years, 2 women.
- 4/5, no preexisting medical conditions.
- All received methylprednisolone, antivirals pretransfusion, and were mechanically ventilated.
- Viral load became negative 1-12 days postinfusion.
- Sequential Organ Failure Assessment scores declined from 2-10 (range) preinfusion to 1-4 at 12 days postinfusion.
- Pao2/Fio2 ratio improved in 4/5 patients 7 days postinfusion (range, 206-290), increasing substantially (range, 284-366) on day 12.
- Body temperature declined to normal at 3 days postinfusion.
- Computed tomography: pulmonary lesion improvement seen at day 3 in 1 patient, gradual resolution seen in 3 patients.
- Immunoglobulin G and M titers increased time-dependently.
- ARDS resolution at day 12 in 4.
- 3 patients were weaned from mechanical ventilation 2-9 days postinfusion.
- At report publication, 3/5 were discharged; remaining 2 were stable at day 37 posttransfusion.
- Case series, Shenzhen, China.
- Funding: National Science and Technology Major Project.
- Inability to measure correlation between administration timing, outcomes.